Mast cell signaling and its role in urticaria
Ann Allergy Asthma Immunol. 2024 Apr 23:S1081-1206(24)00242-4. doi: 10.1016/j.anai.2024.04.023. Online ahead of print.ABSTRACTChronic urticaria (CU) is a mast cells (MC)-driven disease characterized by the development of itching wheals and/or angioedema. In the last decades, outstanding progress has been made in defining the mechanisms involved in MC activation, and novel activating and inhibitory receptors expressed in MC surface were identified and characterized. Besides an IgE-mediated activation via FcεRI-cross-linking, other activating receptors, including Mas-related G protein-coupled receptor-X2 (MRGPRX2), C5a rece...
Source: Annals of Allergy, Asthma and Immunology - April 25, 2024 Category: Allergy & Immunology Authors: Ilaria Puxeddu Francesca Pistone Francesco Pisani Francesca Levi-Schaffer Source Type: research
Chronic Spontaneous Urticaria
Chronic spontaneous urticaria (CSU) affects 0.5% to 1% of the general population and is often managed by allergy and immunology specialists. Guidelines have evolved over the past several decades with an emphasis on decreasing extensive screening laboratory testing as they are of low-yield and cost-ineffective. The utility of biomarkers remains under investigation but total immunoglobulin E may be helpful in determining specific endotypes and response to omalizumab. Antihistamines and omalizumab remain the primary therapeutic options for CSU, but an expanding body of evidence supports the use of immunosuppressants and anti-...
Source: Immunology and Allergy Clinics of North America - April 25, 2024 Category: Allergy & Immunology Authors: Shyam R. Joshi, Karen M. Anstey, David A. Khan Source Type: research
An update on the use of antihistamines in managing chronic urticaria
Expert Opin Pharmacother. 2024 Apr 23. doi: 10.1080/14656566.2024.2345731. Online ahead of print.ABSTRACTINTRODUCTION: Urticaria, a mast cell-mediated skin disease, manifests as acute or chronic, with the latter divided into spontaneous and inducible types and requires individualized management, including identifying triggers and comorbidities. Antihistamines, particularly the second generation group, form the mainstay of primary treatment plans consisting of dosage adjustments and/or in combination with other treatment modalities depending on underlying disease control.AREAS COVERED: A literature search was conducted usin...
Source: Expert Opinion on Pharmacotherapy - April 24, 2024 Category: Drugs & Pharmacology Authors: Yi-Kui Xiang Jie Shen Fok Indrashis Podder Muhammed Burak Y ücel Defne Özkoca Simon Francis Thomsen Emek Kocat ürk Source Type: research
Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022
CONCLUSION: Findings from our analysis of reports to CAEFISS and CVD following vaccination with SIV are consistent with the known safety profile of SIVs distributed during the 2021/2022 influenza season. The majority of reports were non-serious with the most common AEFI symptoms occurring at the vaccination site or systemic symptoms that were self-limiting. The majority of vaccination error reports involved the administration of the vaccine at an inappropriate site, although no serious AEFIs were reported.PMID:38655243 | PMC:PMC11037881 | DOI:10.14745/ccdr.v50i12a02 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - April 24, 2024 Category: Infectious Diseases Authors: Elissa Giang Yuhui Xu Thivya Naganathan Natalia Abraham Marie-Th érèse Bawolak Battouli Said Salim Ashley Weeks Amanda Shaw Susanna Ogunnaike-Cooke Source Type: research
An update on the use of antihistamines in managing chronic urticaria
Expert Opin Pharmacother. 2024 Apr 23. doi: 10.1080/14656566.2024.2345731. Online ahead of print.ABSTRACTINTRODUCTION: Urticaria, a mast cell-mediated skin disease, manifests as acute or chronic, with the latter divided into spontaneous and inducible types and requires individualized management, including identifying triggers and comorbidities. Antihistamines, particularly the second generation group, form the mainstay of primary treatment plans consisting of dosage adjustments and/or in combination with other treatment modalities depending on underlying disease control.AREAS COVERED: A literature search was conducted usin...
Source: Expert Opinion on Pharmacotherapy - April 24, 2024 Category: Drugs & Pharmacology Authors: Yi-Kui Xiang Jie Shen Fok Indrashis Podder Muhammed Burak Y ücel Defne Özkoca Simon Francis Thomsen Emek Kocat ürk Source Type: research
Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022
CONCLUSION: Findings from our analysis of reports to CAEFISS and CVD following vaccination with SIV are consistent with the known safety profile of SIVs distributed during the 2021/2022 influenza season. The majority of reports were non-serious with the most common AEFI symptoms occurring at the vaccination site or systemic symptoms that were self-limiting. The majority of vaccination error reports involved the administration of the vaccine at an inappropriate site, although no serious AEFIs were reported.PMID:38655243 | PMC:PMC11037881 | DOI:10.14745/ccdr.v50i12a02 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - April 24, 2024 Category: Infectious Diseases Authors: Elissa Giang Yuhui Xu Thivya Naganathan Natalia Abraham Marie-Th érèse Bawolak Battouli Said Salim Ashley Weeks Amanda Shaw Susanna Ogunnaike-Cooke Source Type: research
Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022
CONCLUSION: Findings from our analysis of reports to CAEFISS and CVD following vaccination with SIV are consistent with the known safety profile of SIVs distributed during the 2021/2022 influenza season. The majority of reports were non-serious with the most common AEFI symptoms occurring at the vaccination site or systemic symptoms that were self-limiting. The majority of vaccination error reports involved the administration of the vaccine at an inappropriate site, although no serious AEFIs were reported.PMID:38655243 | PMC:PMC11037881 | DOI:10.14745/ccdr.v50i12a02 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - April 24, 2024 Category: Infectious Diseases Authors: Elissa Giang Yuhui Xu Thivya Naganathan Natalia Abraham Marie-Th érèse Bawolak Battouli Said Salim Ashley Weeks Amanda Shaw Susanna Ogunnaike-Cooke Source Type: research
Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022
CONCLUSION: Findings from our analysis of reports to CAEFISS and CVD following vaccination with SIV are consistent with the known safety profile of SIVs distributed during the 2021/2022 influenza season. The majority of reports were non-serious with the most common AEFI symptoms occurring at the vaccination site or systemic symptoms that were self-limiting. The majority of vaccination error reports involved the administration of the vaccine at an inappropriate site, although no serious AEFIs were reported.PMID:38655243 | PMC:PMC11037881 | DOI:10.14745/ccdr.v50i12a02 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - April 24, 2024 Category: Infectious Diseases Authors: Elissa Giang Yuhui Xu Thivya Naganathan Natalia Abraham Marie-Th érèse Bawolak Battouli Said Salim Ashley Weeks Amanda Shaw Susanna Ogunnaike-Cooke Source Type: research
Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022
CONCLUSION: Findings from our analysis of reports to CAEFISS and CVD following vaccination with SIV are consistent with the known safety profile of SIVs distributed during the 2021/2022 influenza season. The majority of reports were non-serious with the most common AEFI symptoms occurring at the vaccination site or systemic symptoms that were self-limiting. The majority of vaccination error reports involved the administration of the vaccine at an inappropriate site, although no serious AEFIs were reported.PMID:38655243 | PMC:PMC11037881 | DOI:10.14745/ccdr.v50i12a02 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - April 24, 2024 Category: Infectious Diseases Authors: Elissa Giang Yuhui Xu Thivya Naganathan Natalia Abraham Marie-Th érèse Bawolak Battouli Said Salim Ashley Weeks Amanda Shaw Susanna Ogunnaike-Cooke Source Type: research
Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022
CONCLUSION: Findings from our analysis of reports to CAEFISS and CVD following vaccination with SIV are consistent with the known safety profile of SIVs distributed during the 2021/2022 influenza season. The majority of reports were non-serious with the most common AEFI symptoms occurring at the vaccination site or systemic symptoms that were self-limiting. The majority of vaccination error reports involved the administration of the vaccine at an inappropriate site, although no serious AEFIs were reported.PMID:38655243 | PMC:PMC11037881 | DOI:10.14745/ccdr.v50i12a02 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - April 24, 2024 Category: Infectious Diseases Authors: Elissa Giang Yuhui Xu Thivya Naganathan Natalia Abraham Marie-Th érèse Bawolak Battouli Said Salim Ashley Weeks Amanda Shaw Susanna Ogunnaike-Cooke Source Type: research
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
CONCLUSIONS: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.PMID:38652814 | DOI:10.1158/1078-0432.CCR-23-3431 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Mario E Lacouture Elena Goleva Neil Shah Veronica Rotemberg Lukas Kraehenbuehl Kwami F Ketosugbo Taha Merghoub Tara Maier Alexander Bang Stephanie Gu Trina Salvador Andrea P Moy Taras Lyubchenko Olivia Xiao Clifton F Hall Evgeny Berdyshev James Crooks Rya Source Type: research
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
CONCLUSIONS: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.PMID:38652814 | DOI:10.1158/1078-0432.CCR-23-3431 (Source: Cancer Control)
Source: Cancer Control - April 23, 2024 Category: Cancer & Oncology Authors: Mario E Lacouture Elena Goleva Neil Shah Veronica Rotemberg Lukas Kraehenbuehl Kwami F Ketosugbo Taha Merghoub Tara Maier Alexander Bang Stephanie Gu Trina Salvador Andrea P Moy Taras Lyubchenko Olivia Xiao Clifton F Hall Evgeny Berdyshev James Crooks Rya Source Type: research
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
CONCLUSIONS: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.PMID:38652814 | DOI:10.1158/1078-0432.CCR-23-3431 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Mario E Lacouture Elena Goleva Neil Shah Veronica Rotemberg Lukas Kraehenbuehl Kwami F Ketosugbo Taha Merghoub Tara Maier Alexander Bang Stephanie Gu Trina Salvador Andrea P Moy Taras Lyubchenko Olivia Xiao Clifton F Hall Evgeny Berdyshev James Crooks Rya Source Type: research
Mast cell signaling and its role in urticaria
Chronic urticaria (CU) is a mast cells (MC)-driven disease characterized by the development of itching wheals and/or angioedema. In the last decades, outstanding progress has been made in defining the mechanisms involved in MC activation, and novel activating and inhibitory receptors expressed in MC surface were identified and characterized. Besides an IgE-mediated activation via Fc εRI-cross-linking, other activating receptors, including Mas-related G protein–coupled receptor-X2 (MRGPRX2), C5a receptor and protease-activated receptors (PAR1 and PAR2) are responsible for MC activation. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - April 23, 2024 Category: Allergy & Immunology Authors: Ilaria Puxeddu, Francesca Pistone, Francesco Pisani, Francesca Levi-Schaffer Tags: Review Source Type: research
Emerging Therapeutics in Chronic Urticaria
Chronic urticaria (CU) is a common and long-lasting mast cell-mediated skin disease associated with psychiatric and autoimmune comorbidities, high economic costs, and considerable impact on quality of life. Available therapies show limited efficacy in many CU patients, which may be related to distinct underlying pathophysiology. Targeted and disease-modifying treatments with higher and broader efficacy are needed and are under development for CU. These novel drugs, small molecules, and monoclonal antibodies target mast cells and their receptors, signaling pathways, or mediators and other immune cells. In this article, the ...
Source: Immunology and Allergy Clinics of North America - April 23, 2024 Category: Allergy & Immunology Authors: Melba Mu ñoz, Emek Kocatürk, Marcus Maurer, Pavel Kolkhir Source Type: research
